My take of the Dec. 7th CC. Not much new but wh
Post# of 148170
(Total Views: 763)
Posted On: 12/13/2022 6:24:30 AM
My take of the Dec. 7th CC.
Not much new but what was already known was well presented.
But the one thing new is a wondrous thing. The results from the one macaque treated with AAV leronlimab is even greater than it appears. A functional cure for HIV would be amazing. What about other long term diseases Long Covid, ME/CFS, Alzheimer's, Parkinson's, ALS, diabetes, recurrent cancers and so many more. Only one shot to help long suffering patients would be a blessing.
With just one subject in the study only scientists and doctors focusing on HIV are paying attention. Once a multi-subject study is done and the clinical holds are lifted proving safety that news should become widespread on HIV.
The future: The downside is that very long term HIV trials would need to be conducted to prove out safety in a drug that completely alters the immune system. Meanwhile Cytodyn can conduct it's other trials, gain approval and build up a war chest on it's 2031 expiration patent. Part of that war chest can be used to license the AAV patent from OHSU and will have further protection via that patent farther into the future.
Not much new but what was already known was well presented.
But the one thing new is a wondrous thing. The results from the one macaque treated with AAV leronlimab is even greater than it appears. A functional cure for HIV would be amazing. What about other long term diseases Long Covid, ME/CFS, Alzheimer's, Parkinson's, ALS, diabetes, recurrent cancers and so many more. Only one shot to help long suffering patients would be a blessing.
With just one subject in the study only scientists and doctors focusing on HIV are paying attention. Once a multi-subject study is done and the clinical holds are lifted proving safety that news should become widespread on HIV.
The future: The downside is that very long term HIV trials would need to be conducted to prove out safety in a drug that completely alters the immune system. Meanwhile Cytodyn can conduct it's other trials, gain approval and build up a war chest on it's 2031 expiration patent. Part of that war chest can be used to license the AAV patent from OHSU and will have further protection via that patent farther into the future.
(23)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼